Vertex Pharmaceuticals Incorporated
Modulators of cystic fibrosis transmembrane conductance regulator
Last updated:
Abstract:
The present invention features a compound of formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
Status:
Grant
Type:
Utility
Filling date:
31 Mar 2020
Issue date:
30 Aug 2022